技术资料

产品手册
细胞治疗研究工具

品牌：

ImmunoCult
52:23

线上讲座
Human iPSC BBB Models for Studying Immune Cell Interactions

发布日期: 11/01/2022
实验方案
Optimizing Delivery Efficiency with Fluorescent Dextran Using the CellPore™ Transfection System

研究方向：

免疫学，疾病建模，药物发现和毒理检测
实验方案
How to Differentiate hPSCs to Lymphoid-Competent CD34+ Hematopoietic Stem and/or Progenitor Cells Using a Scalable Suspension Protocol

研究方向：

免疫学，细胞疗法开发
实验方案
Gene Editing Human Pluripotent Stem Cells (hPSCs) Using the CellPore™ Transfection System

研究方向：

免疫学，疾病建模，药物发现和毒理检测
56:09

线上讲座
Modeling Alzheimer's risk using human TREM2-knockout microglia

发布日期: 02/11/2021
实验方案
如何从多能干细胞生成NK细胞

研究方向：

免疫学，干细胞生物学
实验方案
如何从多能干细胞生成T细胞

研究方向：

免疫学，干细胞生物学，细胞疗法开发
29:54

线上讲座
ISSCR Innovation Showcase: Differentiating Immune Cells from Human Pluripotent Stem Cells in Feeder- and Serum-Free Cultures

发布日期: 08/17/2020
产品手册
消除基因组编辑的不确定性

品牌：

ArciTect
Chen H et al. (DEC 2015) Biological research 48 1 59

Functional disruption of human leukocyte antigen II in human embryonic stem cell.

BACKGROUND Theoretically human embryonic stem cells (hESCs) have the capacity to self-renew and differentiate into all human cell types. Therefore,the greatest promise of hESCs-based therapy is to replace the damaged tissues of patients suffering from traumatic or degenerative diseases by the exact same type of cells derived from hESCs. Allograft immune rejection is one of the obstacles for hESCs-based clinical applications. Human leukocyte antigen (HLA) II leads to CD4(+) T cells-mediated allograft rejection. Hence,we focus on optimizing hESCs for clinic application through gene modification. RESULTS Transcription activator-like effector nucleases (TALENs) were used to target MHC class II transactivator (CIITA) in hESCs efficiently. CIITA (-/-) hESCs did not show any difference in the differentiation potential and self-renewal capacity. Dendritic cells (DCs) derived from CIITA (-/-) hESCs expressed CD83 and CD86 but without the constitutive HLA II. Fibroblasts derived from CIITA (-/-) hESCs were powerless in IFN-$\$ expression of HLA II. CONCLUSION We generated HLA II defected hESCs via deleting CIITA,a master regulator of constitutive and IFN-$\$ expression of HLA II genes. CIITA (-/-) hESCs can differentiate into tissue cells with non-HLA II expression. It's promising that CIITA (-/-) hESCs-derived cells could be used in cell therapy (e.g.,T cells and DCs) and escape the attack of receptors' CD4(+) T cells,which are the main effector cells of cellular immunity in allograft. View Publication

产品号#：

05850

05857

05870

05875

85850

85857

85870

85875

产品名：

mTeSR™1

mTeSR™1
Liu J et al. (NOV 2015) Nature Protocols 10 11 1842--59

Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells.

Targeted nucleases,including zinc-finger nucleases (ZFNs),transcription activator-like (TAL) effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9),have provided researchers with the ability to manipulate nearly any genomic sequence in human cells and model organisms. However,realizing the full potential of these genome-modifying technologies requires their safe and efficient delivery into relevant cell types. Unlike methods that rely on expression from nucleic acids,the direct delivery of nuclease proteins to cells provides rapid action and fast turnover,leading to fewer off-target effects while maintaining high rates of targeted modification. These features make nuclease protein delivery particularly well suited for precision genome engineering. Here we describe procedures for implementing protein-based genome editing in human embryonic stem cells and primary cells. Protocols for the expression,purification and delivery of ZFN proteins,which are intrinsically cell-permeable; TALEN proteins,which can be internalized via conjugation with cell-penetrating peptide moieties; and Cas9 ribonucleoprotein,whose nucleofection into cells facilitates rapid induction of multiplexed modifications,are described,along with procedures for evaluating nuclease protein activity. Once they are constructed,nuclease proteins can be expressed and purified within 6 d,and they can be used to induce genomic modifications in human cells within 2 d. View Publication

产品号#：

05850

05857

05870

05875

07920

17952

17952RF

19052

19052RF

18000

15470

15450

15420

15460

15425

15465

15430

15415

85850

85857

85870

85875

100-0696

07922

产品名：

ACCUTASE™

EasySep™人CD4+ T细胞分选试剂盒

RoboSep™ 人CD4+ T细胞分选试剂盒

EasySep™人CD4+ T细胞富集试剂盒

RoboSep™ 人CD4+ T细胞富集试剂盒含滤芯吸头

EasySep™磁极

mTeSR™1

mTeSR™1

EasySep™人CD4+ T细胞分离试剂盒

ACCUTASE™